Abstracts - faqs.org

Abstracts

News, opinion and commentary

Search abstracts:
Abstracts » News, opinion and commentary

Patent disputes: The issues

Article Abstract:

A discussion on the U.S. patent system, legal disputes, infringement battles, and related judicial cases is presented. High-tech industries such as Microsoft, Oracle and Cisco Systems propose an overhaul of the system, while drug manufacturers and biotechnology companies resist the proposal because making patents harder to enforce would reduce incentives for research and development, thus curtailing technological innovation.

Author: Jost, Kenneth
Publisher: Congressional Quarterly, Inc.
Publication Name: CQ Researcher
Subject: News, opinion and commentary
ISSN: 1056-2036
Year: 2006
Forecasts, trends, outlooks, High technology industry, Industry forecasts

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Rivals Laying Siege to Amgen's Near Monopoly in Anemia Drugs

Article Abstract:

Sales of Amgen Inc.'s anemia drugs, Epogen and Aranesp, are expected to account for nearly half of its $12 billion revenue this year. Since the original patents on these drugs has run out in Europe, several other pharmaceutical companies, including Roche, are developing generic versions.

Author: Pollack, Andrew
Publisher: The New York Times Company
Publication Name: The New York Times
Subject: News, opinion and commentary
ISSN: 0362-4331
Year: 2005
Sales, profits & dividends, Switzerland, Economic aspects, Anemia, Drug therapy, Company sales and earnings, Company earnings/profit, Amgen Inc., AMGN, Roche Holding Ltd., Monopolistic competition, Epogen (Medication), Procrit (Medication)

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Investing for a Profit and a Daughter's Health

Article Abstract:

Allen Andersson invested much of his own money in order to enable the development of Amylin Pharmaceuticals Inc.'s diabetes drug, Symlin, for his sick daughter.

Author: Pollack, Andrew
Publisher: The New York Times Company
Publication Name: The New York Times
Subject: News, opinion and commentary
ISSN: 0362-4331
Year: 2005
Financial management, Government regulation, Executive changes & profiles, Officials and employees, Finance, Company investment, Investments, Licensing, certification and accreditation, Company financing, Andersson, Allen, Amylin Pharmaceuticals Inc., AMLN, Symlin (Medication)

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: United States, Interpretation and construction, Company legal issue, Cases, Pharmaceutical industry, Intellectual property, Patent law, Patent infringement, Product development
Similar abstracts:
  • Abstracts: Caring for the elderly: The issues. Evaluating Head Start: The issues
  • Abstracts: Philanthropy in America: The issues. Prison reform: Throw away the key
  • Abstracts: Sun Life cites credit recovery for 9% profit rise. Growth back on CIBC's agenda. Sun Life profit slow to rise in China
  • Abstracts: Draft debates: Draft rumors still "alive and well". Draft debates: Rumors of Iraqi draft
  • Abstracts: Draft debates: Money woes. Methamphetamine: Helping Meth's youngest victims. Labor unions' future: Busting unions
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.